EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Personalized Medicine in Psoriasis – A Long Road Ahead?

Tom M Hillary iD

Psoriasis: Targets and Therapy · 2026-06 · Volume 16 · 1-3

DOI: 10.2147/ptt.s595079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psoriasis: Targets and Therapy, 2026-06. Verfasst von Tom M Hillary. Beteiligte Einrichtung: Department of Dermatology, University Hospital Leuven, Leuven, Belgium. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic therapies targeting IL‑17 and IL‑23 have revolutionized psoriasis management, enabling rapid and durable disease control. Yet treatment selection still follows a trial‑and‑error approach, and clinically validated biomarkers for personalization remain absent.

Objective

To outline current challenges in biomarker development for psoriasis and describe the design and aims of the PICASSO prospective cohort as a platform for future personalized medicine. Current Challenges: Despite evidence that IL‑17/IL‑23 inhibitors may induce disease modification through effects on effector, memory, and regulatory immune cells, reliable predictive or prognostic biomarkers have not emerged. Barriers include complex pathogenesis, universally high biologic efficacy reducing need for stratification, inconsistent findings from genetic or transcriptomic studies, and the multifactorial nature of comorbidities.

Methods

Picasso ProspectIve Cohort psoriASiS FOllow-Up: PICASSO is a 10‑year prospective biobank/registry enrolling patients within three years of disease onset. Biological samples are longitudinally linked to clinical and epidemiological data, with follow‑ups every 2.5 years. The ultimate aim is to identify biomarkers predicting disease trajectory.

Conclusion

Personalized psoriasis care requires biomarkers predicting progression and comorbidity risk. PICASSO represents a step toward disease‑modifying, preventive precision medicine.

Schlagwörter

Stichwörter der Autor:innen

dermatologydisease modificationpersonalized treatmentresearch

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Leuven, Leuven, Belgium.

ORCID-Profile: Tom M Hillary

Zitieren

APA

Hillary, T. M. (2026). Personalized Medicine in Psoriasis – A Long Road Ahead?. Psoriasis: Targets and Therapy, Volume 16, 1-3. https://doi.org/10.2147/ptt.s595079

Vancouver

Hillary TM. Personalized Medicine in Psoriasis – A Long Road Ahead?. Psoriasis: Targets and Therapy. 2026;Volume 16:1-3. doi:10.2147/ptt.s595079

BibTeX
@article{Hillary2026,
  author = {Hillary, Tom M},
  title = {Personalized Medicine in Psoriasis – A Long Road Ahead?},
  journal = {Psoriasis: Targets and Therapy},
  year = {2026},
  volume = {Volume 16},
  pages = {1--3},
  doi = {10.2147/ptt.s595079}
}
Kostenlos starten →